Immutep has provided a clinical development update for its first-in-class LAG-3 antigen-presenting cell, activator product candidate, eftilagimod alpha, and announced a major appointment to its board. …
Immutep provides clinical update on 'efti' and confirms board appointment
September 14, 2022 Australian Biotech
Latest Video
New Stories
-
Mark Butler: Patients waiting too long and 'as the Health Minister, of course, I am sorry for that'
March 24, 2025 - - Latest News -
Call for safety net change with half a million Australians missing out on cheaper medicines
March 24, 2025 - - Latest News -
Nanotechnology could improve odds in treating aggressive breast cancers
March 24, 2025 - - Latest News -
Industry pushes back on conspiracy theories, highlighting the Government's own comments
March 22, 2025 - - Latest News -
Medicines Australia announces appointment of new board chair
March 20, 2025 - - Latest News -
The 'Week in Review Dispatched' Podcast - 21 March
March 20, 2025 - - Podcast -
New NZ approval clears the way for expanded access to cystic fibrosis therapy
March 20, 2025 - - Latest News